GBIO Company Profile and Key Details

GBIO has shown mixed momentum, losing -0.71% over the past week and -9.55% over the past quarter, though year-to-date performance is down -1.58%. Short-term trend indicators are bearishly aligned (SMA20 -4.85%, SMA50 -2.7%, SMA200 5.22%). The stock’s 14-day RSI is 39.71 (weak momentum), while the ATR of 0.19 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -34.88% below its high and over 77.76% above its low.

Generation Bio Co. generated EPS of -$9.35 over the past year. Five-year average earnings growth is -8.29%. Wall Street analysts project EPS growth of 53.82% annually over the next five years. The latest quarter delivered EPS of -$3.20. The next quarter is forecast at -$6.85. Next year's EPS is expected at $15.27. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $7.00. The high target offers 180.9% upside. The low target suggests 31.09% downside. The mean target is $10.83. This offers 102.81% upside. Generation Bio Co. earnings surprise history is a mixed track record. The quarter that ended March 12, 2026, missed forecasts by -41.86%. The prior quarter beat by -74.23%. Over the last six quarters, Apple has recorded several small beats. These include -17.86% in November 06, 2024.

Generation Bio Co. has 6.74 million shares outstanding. The public float is 4.95 million shares, elevated short interest at 2.14% of float. This equals 98.40 thousand shares. The short ratio is 0.47 days. Institutional investors hold 72.65% of the float. Insiders own 14.24%. MCDONOUGH GEOFF holds 1.18 million shares, Rowland Charles A Jr has 534.76 thousand shares and Kerr Douglas has 326.56 thousand shares.

The stock is currently mid-range between its 52-week high and low $3.00 and $7.52. With a market capitalization of about $35.98 million, Generation Bio Co. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.01). Key stats such as the average daily volume over the past year has been around 82.01 thousand shares, trading with heavier-than-usual volume. Headquartered in Cambridge, MA, Generation Bio Co. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yalonda Howze, the company employs approximately 115 people and listed since June 12, 2020. Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases.

Our AI price prediction model suggests that Generation Bio Co. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.93%, with price expected at $5.55 by February 20, 2026, within a range of $5.45 to $5.66 3-Month Outlook: Projected fall of -70.22%, reaching $1.59 by May 07, 2026, with a range of $1.14 to $1.97. 1-Year Outlook: Projected gain of 126.4%, with price at $12.09 by February 05, 2027, within a range of $0.00 to $15.26.

Generation Bio Co. (NASDAQ:GBIO) shares are flat -1.58% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Generation Bio Co. trading at a premium to the broader market with a P/E of -0.57. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $13.41, suggesting 151.12% upside. Our AI forecast model points to short-term strength (3.93% over two weeks), a medium-term fall (-70.22% over three months), and a longer-term gain (126.4% over one year), with expected trading ranges indicating moderate volatility.

Generation Bio Co. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$6.20. This means the shares are trading below this model’s fair value.

Generation Bio Co. trades at a P/E ratio of -0.57, slightly below the S&P 500 average, with a price-to-sales ratio of 2.36 and a price-to-book ratio of 0.71 suggesting the stock is closer to book value. The P/FCF stands at -0.31, also above market averages.